A prospective crossover pilot study to evaluate the use of a topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor inhibitors.

摘要: One of the dose-limiting toxicities epidermal growth factor receptor inhibitors (EGFRIs) is a papulopustular rash that often pruritic and painful. Secondary skin infection can occur from scratching to relieve pruritus. Studies suggest this might be surrogate marker for efficacy; therefore, effective management needed allow patients use EGFRIs without unnecessary dose modifications. In single-center, prospective, crossover study, we evaluated topical gel (Regenecare Wound Gel) relieving pruritus pain EGFRI-induced among oncology patients. The secondary end points were patient satisfaction, adverse effects, EGFRI At occurrence grade 2 rash, started applying study right side their face; after 1 week, they began it both sides face up an additional 5 weeks. Each providers performed facial evaluation rated symptoms satisfaction on questionnaires. Of 20 enrolled, 13 evaluable. Reduction in itch at week was greater (treated) 69% left (untreated) 8%, same 23% (P = 0.01). pattern similar pain, but differences not significant. On average, as being moderately extremely alleviating symptoms, improving appearance, promoting healing found easy apply. No effects documented. Four (31%) required modifications because rash. Taken together, these findings wound rash-associated itching receiving associated with high satisfaction.